THOMASVILLE, Ga., Aug. 15, 2025 /PRNewswire/ -- Flowers Foods, Inc. (NYSE: FLO) today reported financial results for the company's 12-week second quarter ended July 12, 2025.
...
CHATTANOOGA, Tenn., Aug. 14, 2025 /PRNewswire/ -- Miller Industries, Inc. (NYSE: MLR) (the "Company") announced today that it will reduce its workforce by approximately...
CHANDLER, Ariz., Aug. 7, 2025 /PRNewswire/ -- VIAVI (NASDAQ: VIAV) today reported results for its fiscal fourth quarter and fiscal year ended June 28,...
LAUSANNE, Switzerland, Aug. 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug...
Second Quarter 2025 Renewables SBU Adjusted EBITDA Grew 56% Versus Second Quarter 2024
Strategic Accomplishments
On track to add 3.2 GW of new projects in operation in...
Bragar Eagel & Squire, P.C. Litigation Attorneys Encourage Investors Who Suffered Losses IRobot (IRBT) To Contact Him Directly To Discuss Their Options
Bragar Eagel & Squire, P.C. Litigation Attorneys Encourage Investors Who Suffered Losses IRobot (IRBT) To Contact Him Directly To Discuss Their Options
Adjusting dividend by 50% in response to prolonged industry downturnAligning payout size to ensure capital allocation flexibility and a balanced framework that enables higher returns...
DALLAS, July 23, 2025 /PRNewswire/ -- Southwest Airlines Co. (NYSE: LUV) (the "Company") today reported its second quarter 2025 financial results and Company highlights:
Net...
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses IRobot (IRBT) To Contact Him Directly To Discuss Their Options
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses IRobot (IRBT) To Contact Him Directly To Discuss Their Options
Daix (France), New York City (New York, United States), July 9, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced a leadership transition with the appointment of Jason Campagna, MD, PhD, as President of Research and Development (“R&D”) and Chief Medical Officer (“CMO”) and Martine Zimmermann, PharmD, as Executive Vice President (“EVP”) of Regulatory Affairs and Quality Assurance.